Skip to main content
. Author manuscript; available in PMC: 2023 Oct 10.
Published in final edited form as: Cancer Cell. 2022 Sep 29;40(10):1161–1172.e5. doi: 10.1016/j.ccell.2022.08.022

Figure 3. Effects of TMB calibration on clinical outcomes in the MSKCC cohort of patients with NSCLC treated with ICI (n=234 patients).

Figure 3.

A. Impact of tumor-only versus paired tumor/normal TMB on overall survival in ICI-treated patients with NSCLC at MSKCC. Patients were stratified into: (a) true TMB-low (raw TMB<10; tumor/normal TMB<10), true TMB-high (raw TMB≥10; tumor/normal TMB ≥10), and false TMB-high (raw TMB ≥10, tumor/normal TMB<10). B. Impact of TMB calibration on overall survival in ICI-treated patients with NSCLC at MSKCC. Patients were stratified into: (a) true TMB-low (raw TMB<10; calibrated TMB<10), true TMB-high (raw TMB≥10; calibrated TMB ≥10), and false TMB-high (raw TMB ≥10, calibrated TMB<10). cTMB= calibrated TMB; TMBTO= raw tumor-only TMB; TMBTN= paired tumor/normal TMB.